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ABSTRACT 
Objective: Solubility is greater challenges for formulation which can be explain by different technological approaches during the pharmaceutical 
product development and to improve water solubility and drug release respectively.  
Methods: The solid dispersions of nebivolol were prepared in ratio 1:1, 1:3, 1:5 and 1:7 by fusion and solvent evaporation method using PEG 6000 
and PVP K30 as carriers to enhance solubility of compound.  
Results: All the solid dispersions were evaluated for drug content, phase solubility, in vitro dissolution study. Deferential Scanning Calorimetric 
(DSC) and Fourier Transformer Infra Red (FTIR) showed no chemical interaction between the drug and its carriers. Solubility of PEG 6000 and PVP 
K30 indicates a linear relationship (AL
Conclusion: The overall results showed that process of nebivolol transfer from water to carrier solution is more favorable at higher level of PVP 
K30. The solid dispersion of drug: PVP K 30 (1:7 ratio) prepared by solvent evaporation method was found to be optimum in term of solubility and 
dissolution rate. Hence, we can concluded that solubility of nebivolol can be enhanced using this carrier ratio. 
 type of curve) in the investigated polymer concentration range. The Gibb’s free energy showed declined 
trend with increase in the carrier concentrations. The uniformly of drug content was found in all solid dispersions. The drug release obtained from 
different drug-carrier concentration level fitted to different kinetic model and it was found that solid dispersions exhibited fickian diffusional 
characteristics and best fitted to higuchi model. A PVP K30 solid dispersion (1:7 ratio) prepared by solvent evaporation method showed faster 
dissolution rate (94.38 %) in 30 min among studied solid dispersions.. 
Keywords: Nebivolol, Solid dispersion, Fusion method, Solvent evaporation method. 
 
INTRODUCTION 
Based on the permeability of drug, the Biopharmaceutical 
Classification System (BCS) categorizes into two major classes, viz. 
Class II and IV. Drugs which belong to class II of the 
biopharmaceutical classification system (BCS) are characterized by 
high membrane permeability and slow dissolution rate (due to low 
aqueous solubility) [1]. The solubility or dissolution rate of a drug in 
this category is therefore a key factor in determining the rate and 
extent of its absorption.  
Enhancement of the dissolution rate is essential to obtain for 
therapeutic effect and rate-limiting step for bioavailability. Several 
technological methods have been reported for improvement of 
solubility and dissolution rate of poorly water-soluble drugs, namely 
reducing particle size, solubilization in surfactant systems, 
formation of water soluble complexes, strong electrolyte salt 
formation that usually have higher dissolution rates[2], 
manipulation of the solid state of the drug substance to improve 
drug dissolution[3].  
Solid dispersion can be defined as distribution of active ingredients 
in molecular, amorphous, and/or crystalline forms surrounded by 
an inert carrier [4-5]. Formulation of poorly water-soluble drugs as 
solid dispersions leads to a marked improvement in their 
dissolution rates and is often helped by an increase in their relative 
bioavailability [6-7].  
Nebivolol is a beta-adrenergic receptor blocking agent, having very 
low water solubility, which results into poor dissolution rates. The 
main objective of this work was to investigate the possibility of 
improving the solubility and dissolution rate of NEB by preparing 
solid dispersions with various carriers by two different methods viz. 
fusion method and solvent evaporation method. Solid dispersions 
were evaluated for solubility studies, in-vitro dissolution rate studies 
and interaction between drug and carriers using FT-IR, DSC, SEM 
studies. 
MATERIALS AND METHODS 
Materials 
Nebivolol HCl was kindly gifted by Glenmark Generics Limited 
(Colvale) Goa. PEG 6000, PVP K 30 and methanol were obtained 
from CDH Delhi.  
Phase solubility study 
Phase solubility studies were carried out to evaluate the possible 
solubilizing effect of the carrier by adding an excess amount of 
drug to flask containing 10 ml of aqueous solutions containing 
increasing concentrations of PEG 6000 and PVP K 30 (0.1–1% 
w/v). The flasks were placed in a mechanical shaker at 300 rpm 
and room temperature for 24 hour. After 24 hour these solutions 
were filtered and analyzed by UV spectrophotometer.  
The apparent stability constant (K s
Ks = Slope
Intercept (1−Slope )
 …………. (1) 
) was calculated according to 
the following equation [8] 
The Gibbs free energy of transfer (∆G0 tr
∆G0 = −2.303RT log So
Ss
 …………………. (2) 
) of nebivolol from pure 
water to the aqueous solution of carrier was calculated as follows: 
Where S0/SS
Determination of saturation solubility [2] 
 is the ratio of molar solubility of nebivolol in aqueous 
solutions of carrier to that of the same medium without carrier 
Solubility study was performed using agitation method and 
saturated solution of nebivolol was prepared in respective solvent 
media and stirred for 24 hours. The solution was then centrifuged 
for 15 min over 10,000 rpm and filtered through whatmann filter 
paper 0.45 mm. The concentration of nebivolol was determined 
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using UV-visible spectrophotometer (UV-1800, Shimadzu 
corporation) against respective solvent as blank. 
Preparation of solid dispersions 
Fusion method [9] 
Solid dispersion was prepared by melting the weighed amount of 
either of the different carriers separately in a glazed porcelain 
evaporating dish. The carrier was heated to a temperature just 
sufficient to melt it completely. The drug was then added to this 
melt, mixed thoroughly and continuously until a uniform mix is 
obtained where upon the dish was instantly removed from the heat 
source, and immediately cooled to 5°C using ice water mixture. The 
dish was maintained at the specified temperature for period of 5 
minutes or so until solidified hard mass remained. Then allowed to 
air dry at room temperature for 48 hr with intermittent mixing and 
agitation. The dispersions after drying were pulverized using a glass 
mortar and pestle. The pulverized mass was then sifted through a 
#40 sieve to obtain a uniform particle size and stored in desiccators 
at room temperature until further use. The dispersions were 
prepared in different ratios with respect to drug and polymers as 
shown in Table 1. 
Solvent evaporation method [10] 
Solid dispersions were prepared by dissolving weighed amount of 
either of the different carriers separately in a glazed porcelain 
evaporating dish in a quantity of methanol sufficient to dissolve it 
completely. The drug was then added to this solution and mixed 
thoroughly and continuously until the major portion of methanol 
used was volatilized and hard to semisolid mass remained. Then 
allowed to air dry at room temperature for 48 hr with intermittent 
mixing and agitation.  
The dispersions after drying were pulverized using a glass mortar 
and pestle. The pulverized mass was then sifted through a #40 sieve 
to obtain a uniform particle size and stored in desiccators at room 
temperature until further use. The dispersions were made in different 
ratios with respect to drug and polymers as shown in Table 1.  
 








1:1 Fusion method 
F2  1:3  
F3  1:5  
F4  1:7  




F6  1:3  
F7  1:5  
F8  1:7  
  
Solid state characterization  
Fourier Transform Infrared Spectroscopy (FTIR)  
FT-IR spectrum of the pure drug sample was recorded with 
Shimadzu 8400S. The interference study was carried out using FTIR 
analysis. IR spectrum of pure drug, pure polymer and its solid 
dispersions were performed for polymer drug interaction studies 
between 4000 cm-1to 400 cm-1
Differential scanning calorimetric analysis (DSC) 
. 
The possibility of any interaction between the drugs and the carriers 
during different approaches was assessed by carrying out thermal 
analysis of drug as well as the optimized formulation, using DSC. DSC 
analysis was performed using Shimadzu-Thermal Analyzer DSC 60 
(Japan) on 1 to 5 mg samples. Samples were heated in an open 
aluminum pan at a rate of 10°C/min conducted over a temperature 
range of 50 to 300°C under a nitrogen atmosphere.  
Scanning electron microscopy (SEM) 
Morphology of prepared solid dispersion were examined by 
scanning electron microscope (JSM-5610, Tokyo, Japan) operating at 
10.0 kV accelerating voltage. For conventional imaging in the SEM, 
specimens must be electrically conductive, at least at the surface, 
and electrically grounded to prevent the accumulation of 
electrostatic charge at the surface. Therefore the optimized solid 
dispersions were carbon coated before being subject to electron 
scanning. The energy of electron beam was set at 10 kV. 
In-vitro drug release/dissolution studies 
The in vitro dissolution study was performed in a USP Type II 
dissolution test apparatus using 900 ml of phosphate buffer (pH 6.8) 
at 37+0.5 ◦
Drug content uniformity [2] 
C and stirred at 50 rpm for 30 min. Pure nebivolol or its 
equivalent of SD was sprinkled into the dissolution flask. At 
predetermined time intervals, samples of the dissolution medium 
were withdrawn, filtered through a millipore membrane of 0.45 mm 
pore diameter and analyzed spectrophotometrically against a blank 
formulation. 
Sample containing 10 mg of prepared solid dispersion was 
accurately weighed and dissolved in freshly phosphate buffer pH 6.8 
in a 100 ml volumetric flask. Then the volume was made up to 100 
ml with phosphate buffer pH 6.8. From this 1 ml was taken and 
suitable dilutions were made to get 1 μg/ml with phosphate buffer 
pH 6.8. The absorbance of the resulting solution was measured at 
280 nm against blank (phosphate buffer pH 6.8). 
Mathematical models for drug release kinetics 
The in vitro drug release data were fitted to various release kinetic 
models [11-14]
First-order model 
 viz. first-order, Higuchi, Hixson-Crowell cube root, 
Korsemeyer–Peppas and zero-order model employing the following 
set of equations: 
𝑙𝑙𝑙𝑙 𝑀𝑀𝑀𝑀
𝑀𝑀𝑀𝑀
= 𝑘𝑘1𝑀𝑀  …………………………………. (3) 
Zero-order kinetic model 
M0 − Mt = k0 t ……………………………….(4) 
Higuchi model 
Mt = K√t …………………………………….. (5) 
Hixson-Crowell cube root model 
�W0
3 − �Wt




= ktn  
Where M
 …………………………………….. (7) 
o, Mt and M∞  correspond to the drug amount taken at time 
equal to zero, dissolved at a particular time t and at infinite time, 
respectively. The terms Wo and Wt refer to the weight of the drug 
taken initially and at time t, respectively. Various other terms viz. k, 
ko, k1, k1/3
Statistical analysis [16]
 and K refer to the release kinetic constants obtained from 
the linear curves of Korsemeyer–Peppas, zero-order, first-order, 
Hixson-Crowell cube root law and Higuchi model, respectively [15]. 
All the results were expressed as mean value ± standard deviation 
(SD). One way analysis of variance (ANOVA) by using graph pad 
prism 6 XML was used to test for significance, at a 0.5% significance 
level. Statistical difference dealing (P < 0.05) was considered 
significant. 
  
RESULTS AND DISCUSSION 
Phase solubility study: Fig. 1 represents solubility of PEG 6000 and 
PVP K30 indicates a linear relationship (AL type of curve) in the 
investigated polymer concentration range. The Gibb’s free energy of 
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transfer (∆G0 tr) and apparent stability constants (Ks) derived from 
Fig. 1 are shown in Table 2. The plots of drug solubility against the 
polymer concentration (Fig. 1) Table 2 show that all values of ∆G0 tr  
were negative at all levels of carriers, demonstrating spontaneity of 
drug solubilization process. The values show a declining trend with 
increase in the carrier concentration to construing that the process 
is more favorable at higher carrier levels. Table 2 also indicates that 
PVP K30 interaction has a higher Ks value.  The higher Ks
 
 value 
indicates that the binding affinity between PVP K30 is more than 
that of PEG 6000. The results show that in both cases, the solubility 
of PVP K 30 increased with increasing carrier concentration. 
Table 2: Gibbs free energy values and apparent stability 
constants (Ks) of PVP K30 and PEG 6000 interactions 
Concentration of 
carrier (%w/v) 
G◦ tr(j/mol) for various water-soluble 
carriers at 37◦C 
PEG 6000 PVP K 30 
0.1 -79.37 -250.74 
0.25 -154.20 -458.47 
0.50 -394.14 -971.68 
0.75 -663.59 -1214.91 
1 -835.17 -1532.25 
Slope 0.680 0.985 
k 17.8571 s 564.327 
R 0.903 2 0.960 
 
 
Fig. 1: Solubility of nebivolol (g/100 ml) in aqueous solutions of 
PVP K30 and PEG 6000 in water at 37◦
 
C. (Each point represents 
mean of three determinations.) 
Saturation solubility 
Saturation solubility of nebivolol was determined in various 
aqueous media (distilled water, 0.1 N HCL, phosphate buffer pH 6.8 
and methanol). In acidic pH, nebivolol has appreciable solubility 
owing to its ionization and basic nature. It is obvious that it dissolves 
less in the solutions of higher pH in which it remains in a unionized 
form. From the solubility study data nebivolol shows lower 
solubility in water.  
 
Table 3: Solubility study data 
S. No. Solvent media Concentration (mg/ml) 
1 0.1N HCL 0.215 
2 pH 6.8 phosphate buffer 0.115 
3 Water 0.041 
4 Methanol 0.569 
 
Fourier Transform Infrared Spectroscopy (FTIR) analysis 
Fig. 2-6 shows the FTIR spectrum of NEB and its optimized solid 
dispersions. Characteristic peaks of NEB at 1595.02 cm-1 (N-H 
stretching), 3203.54 cm-1 (O-H stretching), and 1101.20 cm-1 
(cyclic ether C-O stretch), 3003.01 cm-1(aryl substituted C=C), 1303 
cm-1 (C-N stretch) and 2923.88 (C-H stretch) were observed. 
Important vibrations in the spectrum of PEG 6000 are the OH 
stretching at 3442.70 cm-1 and C–H stretching at 2887.24 cm-1. The 
spectra of PEG6000 (MA 1:1) solid dispersion (Fig. 4) can be simply 
regarded as the superposition of NEB. The intensities of some peaks 
in PEG had doubled in its solid dispersion indicating the summation 
of intensities of drug and carrier at these peaks and probably a slight 
increase in the crystallinity of PEG.  
This slight increase in crystallinity of PEG might be a reason for 
decrease in solubility with increase in PEG concentration. Slight 
difference was seen in the position of the absorption bands of PEG 
whereas the minor peaks due to NEB were absent indicating 
trapping of NEB inside the PEG matrix. However, the major 
characteristic peaks for NEB were still present. Important vibrations 
in the spectrum of PVP K30 (Fig. 5) are the C-N stretching (tertiary 
amide) at 1541.02 cm−1, C –H stretching at 2954.74 cm−1, C=O 
stretching at 1662.52 cm−1 and C -C stretching at 1290.29 
cm−1.Increase in crystallinity of PVP K30 might be a reason for 
increase in solubility with increase in PVP K30 concentration.  
Slight difference was seen in the position of the absorption bands of 
PVP whereas the minor peaks due to NEB were absent indicating 
NEB was dissolved inside the PVP matrix. The major characteristic 
peaks for NEB were still present. All optimized solid dispersions 
showed characteristic peaks of NEB drug and carriers. These results 
indicated that there is no chemical interaction between drug and 
carrier when formed as solid dispersion. 
 
Fig. 2: FT-IR spectra of Nebivolol 
 
 
Fig. 3: FT-IR spectra of PEG 6000 
 
Fig. 4: FT-IR spectra of PEG 6000 SD 
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Fig. 5: FT-IR spectra of PVP K30 
 
 
Fig. 6: FT-IR spectra of PVP K30 SD 
 
Differential scanning calorimetric analysis (DSC) 
Thermal behavior of pure drug and corresponding drug-carrier 
system is depicted in (Fig. 7) The DSC curve of NEB profiles a sharp 
endothermic peak at 228.78ºC corresponding to its melting, 
indicating its crystalline nature. However, the characteristic 
endothermic peak, corresponding to drug melting was altered in the 
optimized solid dispersion. A complete disappearance of the drug 
melting peak was observed in PVP K30 (SE 1:7) solid dispersion 
(Fig. 7C) which is attributable to the dissolution of drug in the 
melted carrier before reaching its fusion temperature whereas one 
endothermic peak at temperature slightly lower than that of the PVP 
K30 fusion was observed which may be attributed to the fusion of an 
eutectic mixture between NEB and PVP K30. It should also be noted 
that the incorporation of NEB into PVP resulted in a change in the 
peak temperature of the endotherms displayed by the carrier, 
indicating that the presence of higher polymer concentration and 
uniform distribution of drug in the crust of polymer, resulted in 
complete miscibility of molten drug in polymer. Apart from this, no 
polymorphic changes were observed in any of the optimized 
formulations.  
Scanning electron microscopy (SEM) 
For conventional imaging in the SEM, specimens must be electrically 
conductive, at least at the surface, and electrically grounded to 
prevent the accumulation of electrostatic charge at the surface. 
Therefore the optimized solid dispersions were carbon coated 
before being subject to electron scanning. The energy of electron 
beam was set at 10 kV. 
Scanning electron micrograph of pure NEB shows needle shaped 
crystals indicating the crystalline nature of the drug (Fig. 8A). The 
SEM images of selected solid dispersions are shown in Fig. 8C. SEM 
photomicrograph of SE PVP 1:7 shows that the drug particles are 
entrapped within the carrier matrix, confirming FTIR and DSC data 
analyses. This surface modification ensures the decrease in 
crystallinity of the drug particle. These images indicate the change in 
surface morphology of drug particle due to entrapment into the 
respective polymeric matrix. 
In-vitro drug release/dissolution studies 
Fig. 9 summarizes the experimentally determined solubility and 
dissolution of the pure NEB and its solid dispersions in phosphate 
buffer pH 6.8. All drug-carrier combinations showed an increase in 
solubility and dissolution of NEB as compared to pure NEB. 
Amongst, all dispersions PEG 6000 by fusion method and PVP K30 
by solvent evaporation method showed an exceptional increase in 
solubility as well as dissolution of NEB as compared to plain drug. 
This might be due to hydrophilic nature of the carriers. PEG6000 is a 
polymer of ethylene oxide and water which entrap NEB into its 
matrix and enhances the solubility.  
Correlating the solubility data with the concentration of carrier with 
respect to drug, it was observed that with carriers PVP K30, 
solubility increased with increasing concentration of the carrier 
whereas with PEG 6000 increase in solubility of NEB was observed 
with decrease in concentration of carrier. Dissolution profiles of all 
solid dispersion are shown in fig. 9 which indicated that the SD ratio 
1:7 of drug: PVP K30 gives fast dissolution of drug as compared to 
other ratios. The result of drug release it is concluded that the drug 
release in following order F8>F3>F4>F7>F6>F2>F5>F1. Fig. 9 
showed the dissolution profiles of selected solid dispersions as 
compared to plain drug. 
 
 
                                         (A)   
 
                                       (B) 
 
(C) 
Fig. 7: (A) DSC of nebivolol (B) DSC of PVP K30 (C) DSC of nebivolol with PVP K30 
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Fig. 8: Scanning electron micrograph of (A) Pure NEB (B) Pure PVP K30 (C) PVP K30 SD 
 
 
Fig. 9: Dissolution profile of pure nebivolol and their solid 
dispersion 
 
Drug content uniformity 
Drug content of the solid dispersions was found to be between 
94.13-97.14 % as shown in table 4. All the solid dispersions showed 
the presence of high drug content and low standard deviations of the 
results. It indicates that the drug is uniformly dispersed in the 
powder formulation. Therefore, the method used in this study 
appears to be reproducible for preparation of solid dispersion. 
 
Table 4: % Drug content of nebivolol in solid dispersions 
(mean± S.D) 










Mathematical models for drug release kinetics 
Solid dispersions of solvent evaporation method tended to exhibit 
Fickian diffusional characteristics, as the corresponding values of n 
were lower than the standard value for declaring Fickian release 
behaviour, i.e., 0.4500. The goodness of fit for various models 
investigated for binary systems ranked in the order of Higuchi > 
Korsmeyer-peppas > First-order > zero-order > Hixson-Crowell.
 
Table 5: Mathematical models for drug release kinetics 
Code Mathematical models for drug release kinetics 
Zero-order First order Hixon-crowell  Higuchi Korsmeyer-peppas 
Slope R Slope 2 R Slope 2 R Slope 2 R Slope 2 R2 
(SD) 1.241 S 0.869 -0.030 0.899 0.111 0.608 15.61 0.970 2.624 0.905 
(SD) 1.249 F 0.774 -0.034 0.846 0.101 0.430 15.88 0.804 2.263 0.539 
(SD)S = Solid dispersion by solvent evaporation method, (SD)F 
 
= Solid dispersion by fusion method 
Statistical analysis 
Based on in-vitro dissolution performance, the solid dispersion of 
drug: PVP K 30 (1:7) was showed highest drug release (P < 0.05) 
than compare to other solid dispersions 
CONCLUSION 
In the present study an attempt was made to enhance the solubility 
and dissolution of nebivolol. Solid dispersion were prepared using 
different polymers and by using different methods.  
Solid dispersions were further characterized by DSC, SEM and FTIR 
and it showed that the drug crystallinity was decreases with 
increase in polymer concentration. Solid dispersions prepared using 
higher level of PVP K30 (solvent evaporation method) was found to 
be optimum in terms of drug release. Hence, this method can be 
used to increase the solubility and dissolution of poorly water 
soluble drugs. 
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